keyword
MENU ▼
Read by QxMD icon Read
search

phase-3 and carcinoma

keyword
https://www.readbyqxmd.com/read/29791202/different-mr-features-for-differentiation-of-intrahepatic-mass-forming-cholangiocarcinoma-from-hepatocellular-carcinoma-according-to-tumor-size
#1
Ting Ni, Xiao-Sha Shang, Wen-Tao Wang, Xin-Xing Hu, Meng-Su Zeng, Sheng-Xiang Rao
OBJECTIVE: To identify reliable magnetic resonance (MR) features for distinguishing IMCC from hepatocellular carcinoma (HCC) based on tumor size. METHODS: This retrospective study included 395 patients with pathologically confirmed IMCCs (n = 180) and HCCs (n = 215) who underwent preoperative contrast-enhanced MR imaging including diffusion weighted imaging (DWI). MR features were evaluated and clinical data were also recorded. All the characteristics were compared in small (≤3 cm) and large tumor (>3 cm) groups by univariate analysis and subsequently calculated by multivariable logistic regression analysis...
May 23, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29788981/safety-of-pazopanib-and-sunitinib-in-treatment-naive-patients-with-metastatic-renal-cell-carcinoma-asian-versus-non-asian-subgroup-analysis-of-the-comparz-trial
#2
Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, Shunji Takahashi, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Arun Azad, Ian D Davis, Marlene J Carrasco-Alfonso, Bhupinder Nanua, Jackie Han, Qasim Ahmad, Robert Motzer
BACKGROUND: The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-life profiles favor pazopanib. Our report analyzed pazopanib and sunitinib safety in Asian and non-Asian subpopulations. METHODS: Patients were randomized 1:1 to receive pazopanib 800 mg once daily (continuous dosing) or sunitinib 50 mg once daily in 6-week cycles (4 weeks on, 2 weeks off)...
May 22, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29784193/adjuvant-vascular-endothelial-growth-factor-targeted-therapy-in-renal-cell-carcinoma-a-systematic-review-and-pooled-analysis
#3
REVIEW
Maxine Sun, Lorenzo Marconi, Tim Eisen, Bernard Escudier, Rachel H Giles, Naomi B Haas, Lauren C Harshman, David I Quinn, James Larkin, Sumanta K Pal, Thomas Powles, Christopher W Ryan, Cora N Sternberg, Robert Uzzo, Toni K Choueiri, Axel Bex
CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed...
May 18, 2018: European Urology
https://www.readbyqxmd.com/read/29783126/systemic-therapy-for-intermediate-and-advanced-hepatocellular-carcinoma-sorafenib-and-beyond
#4
REVIEW
Jean-Luc Raoul, Masatoshi Kudo, Richard S Finn, Julien Edeline, Maria Reig, Peter R Galle
The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC. More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). A key recommendation in the management of patients receiving sorafenib is to promote close communication between the patient and the physician so that adverse events (AEs) are detected early and severe AEs can be prevented...
May 17, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29779758/assessing-venous-thrombus-in-renal-cell-carcinoma-preliminary-results-for-unenhanced-3d-ssfp-mri
#5
L C Adams, B Ralla, G Engel, G Diederichs, B Hamm, J Busch, F Fuller, M R Makowski
AIM: To test the potential of unenhanced cardiac- and respiratory-motion-corrected three-dimensional steady-state free precession (3D-SSFP) magnetic resonance imaging (MRI) for the assessment of inferior vena cava (IVC) thrombus in patients with clear-cell renal cell carcinoma (cRCC), compared to standard contrast-enhanced (CE)-MRI and CE-computed tomography (CT). MATERIALS AND METHODS: Eighteen patients with cRCC and IVC thrombus, who received CE-MRI and 3D-SSFP at 1...
May 17, 2018: Clinical Radiology
https://www.readbyqxmd.com/read/29779695/successful-treatment-switch-from-lenvatinib-to-sorafenib-in-a-patient-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-intolerant-to-lenvatinib-due-to-severe-proteinuria
#6
Hideaki Goto, Naomi Kiyota, Naoki Otsuki, Yoshinori Imamura, Naoko Chayahara, Hirotaka Suto, Yoshiaki Nagatani, Masanori Toyoda, Toru Mukohara, Ken-Ichi Nibu, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib...
May 17, 2018: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/29775683/viscoelastic-modeling-of-the-fusion-of-multicellular-tumor-spheroids-in-growth-phase
#7
Guillaume Dechristé, Jérôme Fehrenbach, Elena Griseti, Valérie Lobjois, Clair Poignard
BACKGROUND: Since several decades, the experiments have highlighted the analogy of fusing cell aggregates with liquid droplets. The physical macroscopic models have been derived under incompressible assumptions. The aim of this paper is to provide a 3D model of growing spheroids, which is more relevant regarding embryo cell aggregates or tumor cell spheroids. METHODS: We extend the past approach to a compressible 3D framework in order to account for the tumor spheroid growth...
May 15, 2018: Journal of Theoretical Biology
https://www.readbyqxmd.com/read/29774382/iodine-material-density-images-in-dual-energy-ct-quantification-of-contrast-uptake-and-washout-in-hcc
#8
Daniela Pfeiffer, Anushri Parakh, Manuel Patino, Avinash Kambadakone, Ernst J Rummeny, Dushyant V Sahani
PURPOSE: To determine the diagnostic potential of Material Density (MD) iodine images in dual-energy CT (DECT) for visualization and quantification of arterial phase hyperenhancement and washout in hepatocellular carcinomas compared to magnetic resonance imaging (MRI). MATERIALS AND METHODS: The study complied with HIPAA guidelines and was approved by the ethics committee of the institutional review board. Thirty-one patients (23 men, 8 women; age range, 36-87 years) with known or suspected Hepatocellular Carcinoma (HCC) were included...
May 17, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29773662/validation-of-the-16-gene-recurrence-score-in-patients-with-locoregional-high-risk-renal-cell-carcinoma-from-a-phase-3-trial-of-adjuvant-sunitinib
#9
Brian I Rini, Bernard Escudier, Jean-Francois Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D Goddard, Phillip G Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J Motzer, Alain Ravaud
PURPOSE: Adjuvant sunitinib prolonged disease-free survival (DFS) (hazard ratio [HR] 0.76) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov NCT00375674). The 16-gene Recurrence Score (RS) assay was previously developed and validated to estimate risk for disease recurrence in patients with RCC post-nephrectomy. This analysis further validated the prognostic value of RS assay in patients from S-TRAC and explored association of RS results with prediction of sunitinib benefit...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29773661/phase-i-study-of-oncolytic-vaccinia-virus-gl-onc1-in-patients-with-peritoneal-carcinomatosis
#10
Ulrich M Lauer, Martina Schell, Julia Beil, Susanne Berchtold, Ursula Koppenhöfer, Jörg Glatzle, Alfred Königsrainer, Robert Möhle, Dominik Nann, Falko Fend, Christina Pfannenberg, Michael Bitzer, Nisar P Malek
OBJECTIVE: Peritoneal carcinomatosis (PC) is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Since current therapies are mostly ineffective, new thera-peutic approaches are needed. Here, we report on a phase I study designed to assess safety, MTD, and anti-tumor activity of intra-peri-toneal (i.p.) administration of oncolytic vaccinia virus GL-ONC1 in advanced stage PC patients. DESIGN: GL-ONC1 was administered i...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29771417/lncrna-fer1l4-suppressed-cancer-cell-growth-and-invasion-in-esophageal-squamous-cell-carcinoma
#11
W Ma, C-Q Zhang, H-L Li, J Gu, G-Y Miao, H-Y Cai, J-K Wang, L-J Zhang, Y-M Song, Y-H Tian, Y-H Song
OBJECTIVE: To investigate the regulatory effect of long non-coding ribonucleic acid (lncRNA) FER1L4 on biological behaviors of esophageal squamous cell carcinoma (ESCC) cells, such as proliferation and invasion. PATIENTS AND METHODS: The expressions of FER1L4 were detected in 42 pairs of ESCC tissues and corresponding para-carcinoma tissues and 5 kinds of ESCC cell lines via quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Polyethyleneimine (PEI) and liposomes were used for FER1L4 expression or interference elimination assays, respectively...
May 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29771081/-analysis-of-related-factors-of-coins-foreign-bodies-crossing-the-esophagus-in-204-cases-of-children
#12
H L Lv, B Yan, Q H Zhang
Objective: To explore the anti-tumor effect of Stat3 antisense oligodeoxynucleotide on human Hep-2 cell tumor-bearing BALB/c nude mouse, to study the therapeutic value of Stat3 antisense oligodeoxynucleotide on laryngeal cancer. Method: Hep-2 cells from human laryngeal carcinoma in logarithmic phase were inoculated subcutaneously into BALB/c mice to establish a model of human Hep-2 cell tumor-bearing BALB/c mice. They were divided into blank group, control group and different concentrations of AS3 groups(1 group, 2 group, 3 group, 4 group), and then intraperitoneally administered once a day for 4 weeks, measuring body weight twice a week, and the long and short diameters of the tumors were recorded...
May 2018: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/29771043/-the-effect-of-tanshinone-%C3%A2-a-potentiates-the-effects-of-cisplatin-in-fadu-cells-in-vitro-through-downregulation-of-survivin
#13
Y X Zhao, D Luo, Y H Zhang, B Shen, B X Wang, Z F Sun
Objective: The aim of this study is to investigate the inhibitory effect and mechanism of tanshinone ⅡA combined with cisplatin on tumor Fadu cells in pharyngeal squamous cell carcinoma. Method: Cytotoxicity was determined by CCK8 assay. Flow cytometry was used to detect apoptosis and cell cycle distribution. Western blotting was used to assess the protein expression of related signaling proteins. Result: Compared with the two single drug groups treated with Tan ⅡA and DDP respectively, the combination group showed significantly higher anti-proliferative rate ( P <0...
May 20, 2017: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/29769480/5-hydroxy-4-nitro-7-propionyloxy-genistein-inhibited-invasion-and-metastasis-via-inactivating-wnt-b-catenin-signal-pathway-in-human-endometrial-carcinoma-ji-endometrial-cells
#14
Jun Bai, Xin Luo
BACKGROUND Chemotherapy has been assuring more important roles in the treatment of carcinoma. Developing new types of drugs with less adverse effects and low drug resistance has become an important researching focus. The present study aimed to investigate the anticancer effects of 5-hydroxy-4'-nitro-7-propionyloxy-genistein (HNPG) and to elucidate its underlying molecular mechanism. MATERIAL AND METHODS The inhibitory effects of cell viability of HNPG were detected using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay, flat plate clone formation method, and Transwell assay...
May 17, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29768061/structural-re-positioning-in-silico-molecular-modelling-oxidative-degradation-and-biological-screening-of-linagliptin-as-adenosine-3-receptor-adora3-modulators-targeting-hepatocellular-carcinoma
#15
Bassam M Ayoub, Yasmeen M Attia, Mahmoud S Ahmed
Chemical entities with structural diversity were introduced as candidates targeting adenosine receptor with different clinical activities, containing 3,7-dihydro-1H-purine-2,6-dione, especially adenosine 3 receptors (ADORA3). Our initial approach started with pharmacophore screening of ADORA3 modulators; to choose linagliptin (LIN), approved anti-diabetic drug as Dipeptidyl peptidase-4 inhibitors, to be studied for its modulating effect towards ADORA3. This was followed by generation, purification, analytical method development, and structural elucidation of oxidative degraded product (DEG)...
December 2018: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/29759660/extensive-serum-biomarker-analysis-in-patients-with-nasopharyngeal-carcinoma
#16
Daoyuan Gong, Ziping Li, Rui Ding, Min Cheng, Huakun Huang, Aiping Liu, Mei Kang, Haijian He, Ying Xu, Jing Shao, Yong Wang, Chaohui Duan
Nasopharyngeal carcinoma (NPC) is a fast-growing cancer characterized by high occurrences of nodal and distant metastases and poor prognosis. It is therefore important to identify new serum biomarkers for the early diagnosis and prognostic prediction of this disease. The present study identifies biomarkers in NPC patient serum using a solid-phase antibody array detecting the expression profiles of 174 cytokines in a single experiment. ELISA was performed to validate the array results. The levels of TIMP-2, SELL, CCL24, MMP-1, MMP-3, IGF-I and IL-8 were significantly higher in serum from NPC patients, while the levels of MSP-alpha and HCC-4 were lower...
May 11, 2018: Cytokine
https://www.readbyqxmd.com/read/29755117/safety-anti-tumour-activity-and-pharmacokinetics-of-fixed-dose-shr-1210-an-anti-pd-1-antibody-in-advanced-solid-tumours-a-dose-escalation-phase-1-study
#17
Hongnan Mo, Jing Huang, Jiachen Xu, Xuelian Chen, Dawei Wu, Dong Qu, Xi Wang, Bo Lan, Xingyuan Wang, Jianping Xu, Honggang Zhang, Yihebali Chi, Qing Yang, Binghe Xu
BACKGROUND: To assess the safety profile, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of fixed-dose SHR-1210, a novel anti-PD-1 antibody, in advanced solid tumours. METHODS: A total of 36 patients with advanced solid tumours received intravenous SHR-1210 at 60 mg, 200 mg and 400 mg (4-week interval after first dose followed by a 2-week schedule) until disease progression or intolerable toxicity. The concentration of SHR-1210 was detected for pharmacokinetics, and receptor occupancy on circulating T lymphocytes was assessed for pharmacodynamics...
May 14, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29754934/comprehensive-genomic-profiling-of-metastatic-tumors-in-a-phase-2-biomarker-study-of-everolimus-in-advanced-renal-cell-carcinoma
#18
Xin Gao, Opeyemi Jegede, Connor Gray, Paul J Catalano, Jesse Novak, David J Kwiatkowski, Rana R McKay, Daniel J George, Toni K Choueiri, David F McDermott, Sabina Signoretti, Rupal S Bhatt
INTRODUCTION: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus. PATIENTS AND METHODS: An open-label, single-arm phase 2 biomarker study of everolimus 10 mg daily was conducted in metastatic RCC patients...
April 25, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29753637/safety-and-efficacy-of-cabozantinib-in-metastatic-renal-cell-carcinoma-real-world-data-from-an-italian-managed-access-program
#19
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, Enrico Cortesi, Giuseppe Fornarini, Gaetano Facchini, Giacomo Cartenì, Roberto Sabbatini, Gabriella Del Bene, Luca Galli, Claudia Caserta, Andrea Giovanni Multari, Marco Bregni, Francesco Massari, Sebastiano Buti, Ugo De Giorgi, Fable Zustovich, Michele Milella, Fabio Calabrò, Maria Laura Mancini, Giampaolo Tortora, Claudio Vernieri, Daniele Santini, Mariella Sorarù, Riccardo Ricotta, Cristina Masini, Marcello Tucci, Stefano Luzi Fedeli, Cinzia Ortega, Antonella Mecozzi, Raffaele Ratta, Cora N Sternberg, Elena Verzoni
BACKGROUND: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. METHODS: Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between September and December 2016...
April 19, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29752139/intraprocedural-parenchymal-blood-volume-is-a-predictor-of-treatment-response-for-chemoembolization-in-hepatocellular-carcinoma-results-of-a-prospective-study
#20
Nevin de Korompay, Mohammed Alshammari, Darren Klass, Frank Y Chou, John Chung, Stephen Ho, David M Liu
PURPOSE: To evaluate cone-beam parenchymal blood volume (PBV) before and after embolization as a predictor of radiographic response to transarterial chemoembolization in unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A phase IIa prospective clinical trial was conducted in patients with HCCs > 1.5 cm undergoing chemoembolization; 52 tumors in 40 patients with Barcelona Clinic Liver Criteria stage B disease met inclusion criteria. Pre- and postembolization PBV analysis was performed with a semiquantitative best-fit methodology for index tumors, with a predefined primary endpoint of radiographic response at 3 months...
May 8, 2018: Journal of Vascular and Interventional Radiology: JVIR
keyword
keyword
91258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"